Alaxia: signing of a partnership agreement with Stragen to speed up development of new treatment for cystic fibrosis

9 May 2012

The Swiss pharmaceutical group Stragen and the French Lyon-based start-up Alaxia announced on 26th January 2012, they have signed a partnership agreement to support the development of the drug candidate Meveol until registration.

Annie-Claude Bénichou, Stragen Director of Clinical Affairs, has already been acting as expert for the clinical development of Meveol since November 2010. This agreement consolidates the collaboration between the two companies. "To us, the drug candidate's potential in the fight against cystic fibrosis is obvious. We are confident in the future.", said Annie-Claude Bénichou.

Meveol, which has been designated an orphan drug by both the European Union and the US Food and Drug Administration, has already proved in vitro and in vivo efficacy on a wide range of antibiotic-resistant bacterial strains that progressively colonize the lungs of cystic fibrosis patients.

Financial support and additional expertise

If the Swiss group is bringing financial resources to Alaxia, it is also strengthening the start-up's expertise in drug development, clinical trials and registration.

Philippe Bordeau, CEO of Alaxia, underlined: "Stragen will provide us with the additional resources we need to put Meveol on the market."

"If our priority is to bring Meveol to the market for the treatment of cystic fibrosis, other respiratory diseases could be tackled thanks to Alaxia's innovative molecules. This partnership should therefore enable Stragen to grow through a new therapeutic area", added Antoine Tetard, Director of Stragen.

Hope for over 70,000 patients worldwide

Cystic fibrosis (CF) is a life-threatening inherited disease that affects between 70,000 and 100,000 people worldwide. Around 1 European adult out of 25 carries the faulty gene, usually without being aware of it, and can transfer it to his children. Despite scientific advances, there is still no cure for the disease. The average age at death for CF patients today is 24 years old.

Meveol aims to fight chronic respiratory infections in CF patients by bringing directly to the lungs natural molecules that are usually produced endogenously in the human body. It thus offers an efficient and promising alternative to current antibiotics.

This new partnership will allow clinical trials to begin in 2012.

Find out more

Founded in 2008, Alaxia is an innovative biotech company dedicated to the development of medicinal products to fight serious respiratory diseases.

It is based in Lyon, at the heart of one of the world’s most dynamic pharmaceutical and biotechnology clusters.

The owner of multiple patents, the company is building its pipeline through internal research and development on its peroxidase platform. Meveol is the first drug candidate to exit the pipeline.